

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

RxNorm

RRID:SCR_006645

Type: Tool

Proper Citation

RxNorm (RRID:SCR_006645)

Resource Information

URL: <http://www.nlm.nih.gov/research/umls/rxnorm/>

Proper Citation: RxNorm (RRID:SCR_006645)

Description: Ontology that provides a normalized naming system for generic and branded drugs and a tool for supporting semantic interoperation between drug terminologies and pharmacy knowledge base systems. It contains the names of prescription and many over-the-counter drugs available in the United States and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software. It can mediate messages between systems not using the same software and vocabulary. * RxNorm Download Files - contain data consistent with the 2013AB UMLS Metathesaurus Release Files. * RxNorm API - web service for accessing the current RxNorm data set. * RxNorm Browser (RxNav) - a browser for several drug information sources, including RxNorm, RxTerms and National Drug File - Reference Terminology (NDF-RT) . * Current Prescribable Content - subset of currently prescribable drugs found in RxNorm. * RxTerms Drug Interface Terminology - a drug interface terminology derived from RxNorm for prescription writing or medication history recording

Abbreviations: RxNorm

Synonyms: Rx Norm

Resource Type: controlled vocabulary, data or information resource, ontology

Defining Citation: [PMID:22426081](#)

Keywords: umls, drug, pharmacy, clinical, drug pack, medicine, unique identifier, prescribable drug, web service, metathesaurus, generic drug, branded drug, data set, web service, database

Availability: Account required, (UMLS Terminology Services (UTS))

Resource Name: RxNorm

Resource ID: SCR_006645

Alternate IDs: nif-0000-02575

Record Creation Time: 20220129T080237+0000

Record Last Update: 20260919T195115+0000

Ratings and Alerts

No rating or validation information has been found for RxNorm.

No alerts have been found for RxNorm.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 760 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Shih PC, et al. (2026) Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial. *Arthritis & rheumatology* (Hoboken, N.J.), 78(3), 592.

Rhabneh L, et al. (2026) Incidence of new-onset cardiac arrhythmias in cocaine and cannabis users: a retrospective cohort study. *European heart journal. Acute cardiovascular care*, 15(6), 458.

Al Ta'ani O, et al. (2026) Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis. *Clinical and translational gastroenterology*, 17(4), e00974.

Duggal R, et al. (2026) Impact of Early Versus Delayed Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*, 174(3), 671.

Tartaglia E, et al. (2026) Prognostic Impact of New-Onset Atrial Fibrillation After Cardiac Arrest: Observations From a Federated Research Network. *Journal of cardiovascular electrophysiology*, 37(4), 758.

Nyeo SS, et al. (2026) Population-scale sequencing resolves determinants of persistent EBV DNA. *Nature*, 650(8102), 664.

Xiang X, et al. (2026) Drug-induced risk of depression: A 20-year real-world pharmacovigilance analysis based on the FAERS database. *Medicine*, 105(2), e47076.

Gisladdottir U, et al. (2026) Leveraging Large Language Models in Extracting Drug Safety Information from Prescription Drug Labels. *Drug safety*, 49(2), 177.

Hu JC, et al. (2026) State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients. *JAMA health forum*, 7(3), e260012.

Al-Garadi M, et al. (2026) Enhancing cause of death prediction: development and validation of machine learning models using multimodal data across multiple health-care sites. *JAMIA open*, 9(1), ooaf175.

Zeng W, et al. (2026) Associations of surgical menopause and hormone replacement therapy with meningioma development. *Journal of neuro-oncology*, 177(1).

Barchuk A, et al. (2026) Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study. *Acta oncologica (Stockholm, Sweden)*, 65, 193.

Biber S, et al. (2026) Integrating real-world data with gold-standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof-of-concept data platform. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 22(3), e71207.

Amasa S, et al. (2026) Impact of perioperative GLP-1 agonist use on pseudarthrosis rates following single-level anterior cervical discectomy and fusion: a propensity-matched cohort study. *Journal of spine surgery (Hong Kong)*, 12(2), 16.

Zhou D, et al. (2026) Representation learning to advance multi-institutional studies with electronic health record data from US and France. *Nature communications*, 17(1).

Wu JY, et al. (2026) A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction. *Communications medicine*, 6(1).

Abboud I, et al. (2026) Systemic ??-agonist use and lower hazard of glaucoma compared with ?-blockers: a cohort study. *BMJ open ophthalmology*, 11(2).

Eldesouki MH, et al. (2026) Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes. *United European gastroenterology journal*, 14(5), e70238.

Giorgi C, et al. (2026) Long-Term Outcomes After Catheter-Directed Thrombolysis or Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism: A Propensity-Matched Analysis From a TriNetX Database. *Pulmonary circulation*, 16(2), e70329.

Tsai CY, et al. (2026) Association Between PCSK9 Inhibitor Use and Risk of Age-Related Macular Degeneration. *Translational vision science & technology*, 15(5), 29.